The aim of this study was to investigate whether CD26+ LSC and CD26− HSC populations can be identified and discriminated from each other in an unselected cohort of patients with de novo chronic phase (CP) CML. Here, DPP4 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.